4009011139 18916979144 info@yaleedus.com
工作时间:周一至周六 9:00-18:00 , 周日 9:00-15:00
SCI期刊介绍:4.932分,今年或可首超5分!年发文量超1000篇!
2022-05-065518

今天,我们来看看这本SCI期刊:INTERNATIONAL IMMUNOPHARMACOLOGY。从现有的记录来看,AINTERNATIONAL IMMUNOPHARMACOLOGY 的2021年影响因子(JCR2020)是4.932,自引率5.72%。

期刊基本信息

关于此刊的具体情况,大家可以看看:

https://www.sciencedirect.com/journal/international-immunopharmacology

 

来自期刊官网

期刊接受范围

INTERNATIONAL IMMUNOPHARMACOLOGY 的收稿范围,期刊是如此介绍的(截取部分内容),详情请阅读:

https://www.sciencedirect.com/journal/international-immunopharmacology/about/aims-and-scope

International Immunopharmacologyis the primary vehicle for the publication of original research papers pertinent to the overlapping areas ofimmunology,pharmacology,cytokine biology,immunotherapy,immunopathologyandimmunotoxicology. Review articles that encompass these subjects are also welcome.

The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.

......

期刊接受时间

对于 INTERNATIONAL IMMUNOPHARMACOLOGY 的接受时间,我们看了几篇新近发表的:只需1-5个月就可以接受!

  • Received 18 August 2021; Accepted 29 September 2021
  • Received 16 June 2021; Accepted 23 August 2021
  • Received 18 June 2021; Accepted 16 September 2021
  • Received 1 April 2021; Accepted 6 May 2021
  • Received 21 September 2020; Accepted 22 February 2021
  •  

期刊年发文量

对于 INTERNATIONAL IMMUNOPHARMACOLOGY 的发文量,2018年发文490多篇,2019年发文670多篇,2020年发文970多篇,2021年发文1040多篇。

影响因子

即时影响因子计算发现,2022年3月24日,5.626分。按照常规期刊计算方法,以及往年经验,在2022年6月份公布的IF中,它或首超5!期待6月份新IF的公布!

 

投稿网址及网页界面

想必大家对如何投稿,也很感兴趣,这里我们简单介绍一下投稿界面

https://www.editorialmanager.com/intimp/default1.aspx

 

 

如果还没有注册过账户,只需点击“Register Now”注册账户即可!

 

版权声明:本文转自“51选刊”,文章转载只为学术传播,不代表本号观点,无商业用途,版权归原作者所有,如涉及侵权问题,请联系我们,我们将及时修改或删除。

学术互动

添加微信获取最新优惠、出版政策、课程直播信息,随时咨询客服/编辑,了解更多实时资讯

热门推荐